ZA200503023B - Large conductance calcium-activated K channel opener - Google Patents
Large conductance calcium-activated K channel opener Download PDFInfo
- Publication number
- ZA200503023B ZA200503023B ZA200503023A ZA200503023A ZA200503023B ZA 200503023 B ZA200503023 B ZA 200503023B ZA 200503023 A ZA200503023 A ZA 200503023A ZA 200503023 A ZA200503023 A ZA 200503023A ZA 200503023 B ZA200503023 B ZA 200503023B
- Authority
- ZA
- South Africa
- Prior art keywords
- substituted
- alkyl
- mono
- halogen
- alkoxy
- Prior art date
Links
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 title claims description 16
- 239000011575 calcium Substances 0.000 title claims description 16
- 229910052791 calcium Inorganic materials 0.000 title claims description 16
- -1 nitro, amino, hydroxy, carbamoyl Chemical group 0.000 claims description 147
- 125000000217 alkyl group Chemical group 0.000 claims description 135
- 229910052736 halogen Inorganic materials 0.000 claims description 89
- 150000002367 halogens Chemical class 0.000 claims description 89
- 125000003545 alkoxy group Chemical group 0.000 claims description 70
- 125000001424 substituent group Chemical group 0.000 claims description 66
- 125000004414 alkyl thio group Chemical group 0.000 claims description 58
- 125000000623 heterocyclic group Chemical group 0.000 claims description 55
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 49
- 125000003118 aryl group Chemical group 0.000 claims description 43
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 36
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 35
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 35
- 229910052739 hydrogen Inorganic materials 0.000 claims description 27
- 239000001257 hydrogen Substances 0.000 claims description 27
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 24
- 150000003839 salts Chemical class 0.000 claims description 24
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 23
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 22
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 22
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 claims description 21
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 20
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 18
- 125000001589 carboacyl group Chemical group 0.000 claims description 18
- 125000001544 thienyl group Chemical group 0.000 claims description 18
- 150000000565 5-membered heterocyclic compounds Chemical class 0.000 claims description 17
- 125000005236 alkanoylamino group Chemical group 0.000 claims description 12
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 12
- 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 claims description 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 12
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims description 12
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 11
- 125000002915 carbonyl group Chemical class [*:2]C([*:1])=O 0.000 claims description 10
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 claims description 9
- 125000004181 carboxyalkyl group Chemical group 0.000 claims description 9
- 150000002391 heterocyclic compounds Chemical class 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 125000005041 acyloxyalkyl group Chemical group 0.000 claims description 6
- 125000003342 alkenyl group Chemical group 0.000 claims description 6
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 6
- 125000005115 alkyl carbamoyl group Chemical class 0.000 claims description 6
- 125000005242 carbamoyl alkyl group Chemical group 0.000 claims description 6
- 125000004598 dihydrobenzofuryl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 6
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims description 5
- 125000001041 indolyl group Chemical group 0.000 claims description 5
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 4
- 206010036018 Pollakiuria Diseases 0.000 claims description 4
- 206010046543 Urinary incontinence Diseases 0.000 claims description 4
- 125000004423 acyloxy group Chemical group 0.000 claims description 4
- 125000006350 alkyl thio alkyl group Chemical group 0.000 claims description 4
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 125000004043 oxo group Chemical group O=* 0.000 claims description 4
- 125000002071 phenylalkoxy group Chemical group 0.000 claims description 4
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 4
- 125000005083 alkoxyalkoxy group Chemical group 0.000 claims description 3
- 125000005079 alkoxycarbonylmethyl group Chemical group 0.000 claims description 3
- 208000035475 disorder Diseases 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims description 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims description 2
- 238000000034 method Methods 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N Furan Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims 2
- 238000011321 prophylaxis Methods 0.000 claims 2
- XZMCDFZZKTWFGF-UHFFFAOYSA-N Cyanamide Chemical compound NC#N XZMCDFZZKTWFGF-UHFFFAOYSA-N 0.000 claims 1
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 125000005265 dialkylamine group Chemical group 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 108091006146 Channels Proteins 0.000 description 14
- 102000016469 Large-Conductance Calcium-Activated Potassium Channels Human genes 0.000 description 7
- 108010092555 Large-Conductance Calcium-Activated Potassium Channels Proteins 0.000 description 7
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 206010008118 cerebral infarction Diseases 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000028161 membrane depolarization Effects 0.000 description 2
- WYLSGWZVDHQRNX-UHFFFAOYSA-N 2-(3,4-dimethoxy-n-(4-methylphenyl)sulfonylanilino)-n-(2,4-dimethylpentan-3-yl)acetamide Chemical compound C1=C(OC)C(OC)=CC=C1N(CC(=O)NC(C(C)C)C(C)C)S(=O)(=O)C1=CC=C(C)C=C1 WYLSGWZVDHQRNX-UHFFFAOYSA-N 0.000 description 1
- ZVMMRPKNIIGQEN-UHFFFAOYSA-N 7-[(4-chlorophenyl)methyl]-11-[(3-ethynylphenyl)methyl]-2,5,7,11-tetrazatricyclo[7.4.0.02,6]trideca-1(9),5-dien-8-one Chemical compound ClC1=CC=C(CN2C3=NCCN3C3=C(CN(CC4=CC(=CC=C4)C#C)CC3)C2=O)C=C1 ZVMMRPKNIIGQEN-UHFFFAOYSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical class O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 241000692885 Nymphalis antiopa Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000004257 Potassium Channel Human genes 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 125000000278 alkyl amino alkyl group Chemical group 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000009460 calcium influx Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 125000006310 cycloalkyl amino group Chemical group 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 150000002240 furans Chemical class 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000012241 membrane hyperpolarization Effects 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 108020001213 potassium channel Proteins 0.000 description 1
- 239000004036 potassium channel stimulating agent Substances 0.000 description 1
- 230000003805 potassium influx Effects 0.000 description 1
- 150000003233 pyrroles Chemical class 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000036390 resting membrane potential Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/337—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/28—Halogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002300860 | 2002-10-15 | ||
| JP2003104260 | 2003-04-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200503023B true ZA200503023B (en) | 2006-11-29 |
Family
ID=32109456
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200503023A ZA200503023B (en) | 2002-10-15 | 2003-12-15 | Large conductance calcium-activated K channel opener |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US7531655B2 (es) |
| EP (1) | EP1556376B1 (es) |
| JP (1) | JP4657917B2 (es) |
| KR (1) | KR100744358B1 (es) |
| CN (1) | CN1705659A (es) |
| AR (1) | AR041616A1 (es) |
| AT (1) | ATE401324T1 (es) |
| BR (1) | BR0315386A (es) |
| CA (1) | CA2501979A1 (es) |
| DE (1) | DE60322245D1 (es) |
| ES (1) | ES2309340T3 (es) |
| IS (1) | IS7745A (es) |
| MX (1) | MXPA05003972A (es) |
| NO (1) | NO20052023L (es) |
| NZ (1) | NZ539902A (es) |
| PL (1) | PL375890A1 (es) |
| RU (1) | RU2005114524A (es) |
| TW (1) | TWI271402B (es) |
| WO (1) | WO2004035570A1 (es) |
| ZA (1) | ZA200503023B (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200524575A (en) * | 2003-10-27 | 2005-08-01 | S Bio Pte Ltd | Biaryl linked hydroxamates: preparation and pharmaceutical applications |
| JP2005325103A (ja) * | 2004-04-13 | 2005-11-24 | Tanabe Seiyaku Co Ltd | 医薬組成物 |
| WO2005123072A1 (en) * | 2004-06-14 | 2005-12-29 | Sepracor Inc. | Methods and compositions for the treatment of pulmonary diseases |
| US20090035224A1 (en) * | 2004-06-14 | 2009-02-05 | Sepracor Inc. | Methods of Using Albuterol and Calcium Activated Potassium Channel Openers |
| TW200616969A (en) * | 2004-09-17 | 2006-06-01 | Tanabe Seiyaku Co | Imidazole compound |
| US8492428B2 (en) | 2005-09-20 | 2013-07-23 | Mayo Foundation For Medical Education And Research | Small-molecule botulinum toxin inhibitors |
| US8575338B2 (en) * | 2008-04-09 | 2013-11-05 | Mitsubishi Tanabe Pharma Corporation | Pyrimidine, pyridine and triazine derivatives as maxi-K channel openers |
| WO2013009259A1 (en) * | 2011-07-14 | 2013-01-17 | Biochromix Pharma Ab | Novel compounds and their use in therapy |
| FR2993563B1 (fr) * | 2012-07-20 | 2015-12-18 | Metabrain Res | Derives de thiophenes utiles dans le traitement du diabete |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1271082A (en) * | 1968-05-07 | 1972-04-19 | Wyeth John & Brother Ltd | Furan, pyrrole and thiophene derivatives |
| US3743656A (en) * | 1969-05-01 | 1973-07-03 | Wyeth John & Brother Ltd | Thiophene and furan lower alkanoic acids and derivatives |
| US5062169A (en) | 1990-03-09 | 1991-11-05 | Leggett & Platt, Incorporated | Clinical bed |
| ATE141051T1 (de) * | 1992-04-07 | 1996-08-15 | Neurim Pharma 1991 | Verwendung von melatonin zur herstellung eines arzneimittels zur behandlung der gutartigen prostatahyperplasie |
| WO1996010567A1 (fr) * | 1994-09-30 | 1996-04-11 | Maruho Co., Ltd. | Derive d'aminocetone et sel physiologiquement acceptable de celle-ci et leur utilisation |
| AT402926B (de) * | 1994-12-05 | 1997-09-25 | Hafslund Nycomed Pharma | Heterocyclische amide, verfahren zu ihrer herstellung und verwendung |
| US5565483A (en) * | 1995-06-07 | 1996-10-15 | Bristol-Myers Squibb Company | 3-substituted oxindole derivatives as potassium channel modulators |
| US5998459A (en) * | 1995-06-07 | 1999-12-07 | Nippon Shinyaku Co Ltd | Pyrrole derivatives and medicinal composition |
| JPH09278751A (ja) * | 1996-04-12 | 1997-10-28 | Taisho Pharmaceut Co Ltd | ピペラジン誘導体 |
| TW467902B (en) * | 1996-07-31 | 2001-12-11 | Bristol Myers Squibb Co | Diphenyl heterocycles as potassium channel modulators |
| US5869195A (en) | 1997-01-03 | 1999-02-09 | Exxon Research And Engineering Company | Corrosion resistant carbon steel |
| PT853083E (pt) * | 1997-01-06 | 2001-12-28 | Pfizer | Composto de piridilfurano e piridiltiofeno e sua utilizacao farmaceutica |
| JP4306806B2 (ja) * | 1997-04-24 | 2009-08-05 | ダウ・アグロサイエンス・エル・エル・シー | 有害生物防除性 ３―（置換フェニル）―５―（チエニルまたはフリル）―１，２，４―トリアゾール |
| US6020339A (en) * | 1997-10-03 | 2000-02-01 | Merck & Co., Inc. | Aryl furan derivatives as PDE IV inhibitors |
| JPH11302270A (ja) * | 1998-04-22 | 1999-11-02 | Dainippon Pharmaceut Co Ltd | １−〔（５−置換−２−フリル）メチル〕環状アミン誘導体及び関連化合物 |
| JP2000351773A (ja) * | 1999-06-08 | 2000-12-19 | Yamanouchi Pharmaceut Co Ltd | フラン誘導体からなる医薬 |
| IT1320771B1 (it) | 2000-10-26 | 2003-12-10 | Enichem Spa | Leganti tridentati e relativi complessi con metalli di transizione. |
| IL158168A0 (en) * | 2001-04-16 | 2004-03-28 | Tanabe Seiyaku Co | 5-membered, nitrogen-containing heterocyclic compounds and pharmaceutical compositions containing the same |
-
2003
- 2003-10-14 TW TW92128367A patent/TWI271402B/zh not_active IP Right Cessation
- 2003-10-15 RU RU2005114524/04A patent/RU2005114524A/ru not_active Application Discontinuation
- 2003-10-15 US US10/531,330 patent/US7531655B2/en not_active Expired - Fee Related
- 2003-10-15 KR KR1020057006418A patent/KR100744358B1/ko not_active IP Right Cessation
- 2003-10-15 MX MXPA05003972A patent/MXPA05003972A/es unknown
- 2003-10-15 JP JP2005501348A patent/JP4657917B2/ja not_active Expired - Fee Related
- 2003-10-15 WO PCT/JP2003/013194 patent/WO2004035570A1/en active IP Right Grant
- 2003-10-15 DE DE60322245T patent/DE60322245D1/de not_active Expired - Lifetime
- 2003-10-15 ES ES03754140T patent/ES2309340T3/es not_active Expired - Lifetime
- 2003-10-15 PL PL03375890A patent/PL375890A1/xx not_active Application Discontinuation
- 2003-10-15 EP EP03754140A patent/EP1556376B1/en not_active Expired - Lifetime
- 2003-10-15 AT AT03754140T patent/ATE401324T1/de not_active IP Right Cessation
- 2003-10-15 NZ NZ539902A patent/NZ539902A/en unknown
- 2003-10-15 CN CNA2003801015080A patent/CN1705659A/zh active Pending
- 2003-10-15 AR ARP030103742A patent/AR041616A1/es not_active Application Discontinuation
- 2003-10-15 BR BR0315386-0A patent/BR0315386A/pt not_active IP Right Cessation
- 2003-10-15 CA CA002501979A patent/CA2501979A1/en not_active Abandoned
- 2003-12-15 ZA ZA200503023A patent/ZA200503023B/en unknown
-
2005
- 2005-03-15 IS IS7745A patent/IS7745A/is unknown
- 2005-04-26 NO NO20052023A patent/NO20052023L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AR041616A1 (es) | 2005-05-26 |
| NO20052023L (no) | 2005-05-10 |
| AU2003272099A1 (en) | 2004-05-04 |
| CN1705659A (zh) | 2005-12-07 |
| PL375890A1 (en) | 2005-12-12 |
| EP1556376A1 (en) | 2005-07-27 |
| WO2004035570A1 (en) | 2004-04-29 |
| KR20050057654A (ko) | 2005-06-16 |
| ATE401324T1 (de) | 2008-08-15 |
| ES2309340T3 (es) | 2008-12-16 |
| RU2005114524A (ru) | 2006-02-27 |
| IS7745A (is) | 2005-03-15 |
| TWI271402B (en) | 2007-01-21 |
| NZ539902A (en) | 2007-05-31 |
| US7531655B2 (en) | 2009-05-12 |
| KR100744358B1 (ko) | 2007-07-30 |
| US20060135597A1 (en) | 2006-06-22 |
| DE60322245D1 (de) | 2008-08-28 |
| JP2006503111A (ja) | 2006-01-26 |
| JP4657917B2 (ja) | 2011-03-23 |
| MXPA05003972A (es) | 2005-06-22 |
| CA2501979A1 (en) | 2004-04-29 |
| TW200418844A (en) | 2004-10-01 |
| EP1556376B1 (en) | 2008-07-16 |
| BR0315386A (pt) | 2005-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4636520A (en) | Antifungal composition employing pyrrolnitrin in combination with an imidazole compound | |
| ES2344845T3 (es) | Biocidas de metal/tiol. | |
| RU2560846C1 (ru) | Фармацевтические композиции, содержащие сулбактам и ингибитор бета-лактамазы | |
| AU706735B2 (en) | Use of 2-amino-4-(4-fluorobenzylamino)-1-ethoxy- carbonylaminobenzene for prophylaxis and treatment of sequelae of acute and chronic reduced circulation in the brain and neurodegenerative disorders | |
| EP0821586B1 (en) | A pharmaceutical composition containing benzimidazole for inhibiting the growth of cancers | |
| US20110065729A1 (en) | Methods and compositions for ameliorating the undesirable effects of chemotherapy | |
| ZA200401846B (en) | Ihibitors of glycogen synthase kinase-3 (GSK-3) for treating glaucoma. | |
| AU2002334635A1 (en) | Inhibitors of glycogen synthase kinase-3 (GSK-3) for treating glaucoma | |
| NO338380B1 (no) | Anvendelse av et terapeutisk preparat av et PBD-derivat, samt et produkt derav | |
| BG103803A (bg) | Метод за приложение на инхибитори на циклооксигеназа-2 при предотвратяване на смущения в сърдечно-съдовата система | |
| KR20010079616A (ko) | 과도한 물질 ｐ에 의해 야기된 문제점을 치료하기 위한약물 제조에 사용되는 아릴(또는헤테로아릴)아졸일카르비놀 유도체의 용도 | |
| CA2706709A1 (en) | Compositions and methods for treating vaginal infections and pathogenic vaginal biofilms | |
| ZA200503023B (en) | Large conductance calcium-activated K channel opener | |
| US10682360B2 (en) | Antimicrobial formulations and applications thereof | |
| WO2016151543A1 (en) | Pharmaceutical compositions comprising antibacterial agents | |
| US10864222B1 (en) | Beta-lactamase inhibitors, formulations, and uses thereof | |
| ZA200507179B (en) | Crystalline N-formyl hydroxylamine compounds | |
| US5665371A (en) | Medicines which contain derivatives of proline or hydroxyproline | |
| US20180110775A1 (en) | Compositions and methods for treating mitochondrial diseases | |
| JP2007536256A (ja) | 心臓損傷の処置のためのピロロキノリンキノン薬およびその使用方法 | |
| US10874682B2 (en) | Compositions and the use thereof for treating or preventing rosacea | |
| US4291035A (en) | Pharmaceutical compositions comprising trimethoprim and N-ethyl-γ-pyridone-3-carboxylic acid derivatives | |
| CA2445477A1 (en) | Antitumor agents | |
| US4333945A (en) | Thiazoline and imidazoline derivatives useful as minor tranquilizers | |
| Sakai et al. | Nontoxic intravitreal dose of ofloxacin for rabbit retina |